Bristol Myers CEO signals dealmaking will be a top priority in 2025news2025-04-24T15:29:15+00:00April 24th, 2025|Endpoints News|
Roche Q1 earnings: CEO warns that tariffs could impact dealmakingnews2025-04-24T10:12:53+00:00April 24th, 2025|Endpoints News|
China’s biotech market is staging a comeback that US biotech can only wish fornews2025-04-23T14:00:55+00:00April 23rd, 2025|Endpoints News|
Repertoire inks autoimmune deal with Genentech as it eyes a return to the clinicnews2025-04-23T11:00:32+00:00April 23rd, 2025|Endpoints News|
Boehringer taps Tessellate Bio for ALT positive cancer pact exceeding $573M in biobucksnews2025-04-23T07:00:12+00:00April 23rd, 2025|Endpoints News|
China-based VelaVigo inks its second US biotech dealnews2025-04-17T19:00:02+00:00April 17th, 2025|Endpoints News|
Sanofi to pay $125M upfront for two immunology drugs from Earendil Labsnews2025-04-17T14:45:25+00:00April 17th, 2025|Endpoints News|
Ayrmid misses deadline for detailed offer to top private equity bid for bluebirdnews2025-04-16T13:48:58+00:00April 16th, 2025|Endpoints News|
GeneDx to buy Fabric Genomics for up to $51Mnews2025-04-16T10:00:12+00:00April 16th, 2025|Endpoints News|
Small biotech Oak Hill will bring Roche’s Angelman drug back to lifenews2025-04-15T11:00:21+00:00April 15th, 2025|Endpoints News|
